Lansoprazole plus levosulpiride versus esomeprazole in participants with gastroesophageal reflux disease and erosive esophagitis: a double blinded randomized control trial.

Aim: The aim was to compare the efficacy and safety of lansoprazole plus levosulpiride over esomeprazole. Methodology: This randomized control trial recruited 1000 participants having symptomatic gastroesophageal reflux disease (GERD) and erosive esophagitis and they were blindly randomized into two groups in a 1:1 ratio with appropriate concealment. Group 1 was given lansoprazole plus levosulpiride combination twice daily whereas group 2 was prescribed only esomeprazole twice daily. The primary efficacy endpoint was the healing of erosive esophagitis and GERD at week 49. Secondary assessments included improvement in quality of life. Participants' quality of life was assessed before starting the treatment and post-treatment using a short-form health survey questionnaire (SF-36). Results: The lansoprazole plus levosulpiride group had significantly lower rates of positive postintervention GERD and erosive esophagitis status, and higher rates of sustained resolution of heartburn compared to the esomeprazole alone group. However, the lansoprazole plus levosulpiride group also had a higher risk of nausea. Conclusion: Lansoprazole plus levosulpiride is a more effective and safe treatment for GERD than esomeprazole alone. Participants in the lansoprazole plus levosulpiride group showed a significantly higher rate of sustained resolution of GERD, lower rates of postintervention GERD and erosive esophagitis status, and a higher incidence of nausea compared to the esomeprazole alone group. Although quality of life worsened in both groups, adverse effects did not significantly differ. These findings strongly support the use of lansoprazole plus levosulpiride as a preferred treatment option for GERD and erosive esophagitis, which could have significant clinical implications for managing this common condition.

Descompresión Microvascular para el Tratamiento del Espasmo Hemifacial

Resumen El espasmo hemifacial se caracteriza por contracciones tonicoclónicas en los músculos inervados por el nervio facial, causado por la compresión del nervio facial por una arteria, generalmente la arteria cerebelosa anteroinferior o venas del ángulo pontocerebeloso. Suelen aparecer espontáneamente, debido a la tensión emocional, fatiga, y disminuyen durante el reposo. Se presenta entre los 13 a 77 años con una duración de los síntomas aproximadamente de ocho años. La inyección local de toxina botulínica puede ser efectiva en el tratamiento, y la descompresión microvascular está reservada para casos refractarios al tratamiento médico, con resolución completa entre el 85 al 93%. En este artículo, se resumen las principales características anatomo-clínicas, fisiopatológicas, y una descripción detallada de la descompresión microvascular como mejor opción terapéutica.

Abstract Hemifacial spasm is characterized by tonic-clonic contractions of the muscles innervated by the facial nerve. It is caused by compression of the facial nerve by a blood vessel, which usually is the anterior inferior cerebellar artery or the veins of the cerebello-pontine angle. It typically appears spontaneously, caused by emotional tension and fatigue, and it's reduced during rest. Likewise, it presents between the ages of 13 and 77 years, with a median duration of symptoms of eight years. Treatment with local botulinum toxin injection can be effective, and the Microvascular decompression is reserved for cases that are refractory to medical treatment, resulting in full spasm resolution in 85 to 93% of patients. This article summarizes the main anatomic-clinical and physio-pathological characteristics of hemifacial spasms. Additionally, a detailed description of microvascular decompression as the best therapeutic option is described in detail.